Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08WQU
|
|||
| Drug Name |
AEB1102
|
|||
| Indication | Arginase 1 deficiency [ICD-11: 5C50.A2] | Phase 2 | [1] | |
| Small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162.9] | Phase 1/2 | [2] | ||
| Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1 | [2] | ||
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 1 | [2] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 1 | [2] | ||
| Company |
Aeglea Biotherapeutics Austin, TX
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03378531) A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency (AEB1102). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.